Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Industry News

| More

Indian biosimilar market to be worth $40 billion by 2030

Posted On: 2018-11-23 19:00:07

The Confederation of Indian Industry (CII) & Sathguru Management Consultants released a position paper on Indian Biosimilars Industry - "Indian Biosimilars Industry: Roadmap to Actualize Global Leadership" at the 2nd National Biotechnology Conclave 2018 - Driving Inclusive Growth for Indian Bio-economy Vision- 2025 organised by CII in Delhi.

Biosimilars present a very attractive opportunity for Indian pharma companies going beyond small molecule generics ridden with intense competition and price pressures. Based on analysis of currently approved biologic drugs and global pipeline, in the most optimistic scenario, we estimate that the global biosimilar market will be worth of $240 Billion and Indian biosimilars market will be worth of $40 billion by 2030. Growth is being driven by increasing market maturity in Europe, more recent forthcoming environment for regulatory approvals in US and high unmet clinical need across RoW markets.

With record number of domestic approvals, active engagement in semi-regulated markets and growing footprint in regulated markets, the Indian biosimilar industry is poised at the cusp of growth. There are more than 70 biosimilars approved in the country today. The revised Indian guidelines released in 2016 have not only resulted in a rigorous framework for approvals in India, but have also paved the way for leaner bridging effort to enter global markets. At this juncture, it is imperative to nurture the vibrant industry landscape and support the industry in value realization. Major challenges to combat to secure a sustainable future for Indian-made biosimilars and key recommendations are:

1. Expanding markets in domestic landscape: Biosimilars as a means to overcoming affordability barriers is a promise that is a promise that is yet to be translated to reality in several countries including India. Though substantial level of price erosion has been breached, overall market size is currently unattractive as volume penetration remains significantly low. For instance, one of the more mature assets in India, Trastuzumab biosimilar had overall sales of about Rs. 286 crores in 2017 translating to less than 10% penetration when assessed on the basis of overall clinical need. Price control has had insignificant impact on expanding access as overall cost of care in indications such as oncology still remains out of reach for majority of the population. Hence, is it is important to consider other models of aggregated and negotiated buying for public health so that blanket price control can be avoided. It is critical that affordable biologics are included in national coverage programs to expand access, especially at a time when landmark public health programs such as Ayushman Bharat PMJAY are rolled out. Finally, as done in certain European countries with high success in biosimilars adoption, a multi-stakeholder approach has to be engaged to drive greater awareness, clinical adoption and market expansion.

2. Strengthening upstream technology backbone: Sustainable success in the segment will hinge on production economics, especially as prices erode and unit cost and enhanced capex recovery become critical. There is urgent need to strengthen industry's backbone in upstream technology development, especially in areas such as high yielding clones and industry-academia platforms should be explored. For near term impact, globally benchmarkable non-dilutive funding and fiscal incentives for technology acquisition should be considered.

3. Paving the way for sustainable leadership in global markets: As regulated markets embrace biosimilars and move towards higher market maturity, it is optimal time for the industry to expand thrust on regulated markets, that will constitute majority of the near term global markets by value. However, given the significant level of binary risk per asset (clinical development investments of about $100 to $150 million per asset), key to defraying risk and expanding investment appetite will lie in more aggressively pursuing strategic partnerships with global as well as domestic counterparts. The Biocon-Mylan partnership is a great testimony to strategic value of such partnerships and has resulted in Indian developed biosimilars being among the first wave of approved assets in regulated markets. For RoW markets, the WHO PQ presents great promise as a mechanism that can provide aggregated access to multiple markets that are relatively less mature. India should encourage fast tracking of the WHO PQ pilot while pursuing regulatory reciprocity in select markets until such aggregated possibility is a tangible reality. Finally, as done through bodies such as PHARMEXIL in small molecule drugs, a multi-stakeholder approach to enhance global reputation and support global market access will greatly accelerate market expansion in the fragmented RoW markets.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

New HFS report recognizes Cognizant for 'Simplifying Healthcare'

National Life Transforms Customer Experience Program with Cognizant

ETMONEY becomes India's first comprehensive financial services app to integrate UPI

India pharmaceuticals market expected to reach USD 73.5 billion by 2023

Engineers Alert: Zomato opens registrations for its 'Trial Week'

Wadhawan Global Capital sells stake in Avanse to Warburg Pincus

ICAI Postpones May, 2019 CA Examinations

MSE 'Financial Inclusion' Drive in Goa in a bid to Boost Participation from Tier II, Tier III Cities & Rural Areas

Vikram Solar commissions 200 MW solar project for APGENCO

Cognizant Names Brian Humphries as CEO, Succeeding Company Co-Founder Francisco D'souza

Harish Natarajan appointed as the new President and COO of Strand Life Sciences

ICAI Celebrates Platinum Jubilee Annual Function

ICAI signs MoU with Invest India to promote Foreign Investment

Tata AIA Life Insurance celebrates the Centennial Year of AIA

Twenty14 Holdings Marks Entry into Switzerland with new IntercityHotel at Zurich Airport

ICAI signs MoU with ICPA of Kenya

Sathguru Management Consultants advises Pravesha Industries to divest majority stake in Crest Cellulose to Roquette Freres, SA

Saurashtra Freight Pvt. Ltd. charts out growth strategy

Toffee Insurance announces India's First Cyclist Insurance

Whitecaps flags of their 6 month excellence program in cake making

Home Credit India offers attractive customer-focused schemes across Lenovo and Motorola smartphone range

MyLoanCare rolls out a free loan portfolio management system

Auto LPG sector grows impressively; clocks 14% growth in sales

'India Cold Chain Show 2018' showcases innovative cooling solutions in Mumbai

ZestMoney partners with Xiaomi to provide financing options at Mi Home stores

Jana Small Finance Bank launches Jana Bankable Debit Card

GoAir announces Kannur as its 24th domestic destination

InterGlobe Foundation initiates Heritage Restoration and Waste Management In Rajasthan

eMudhra becomes an Executive Member of the Cloud Signature Consortium

ECGC chairs meeting of CEOs of ECAs of Asia Pacific Regional Cooperation Group in Mumbai

Fincare SFB posts 99 percent AUM growth, Rs.42.3 crore profit in H1 FY 2019

Future Generali India Life Insurance introduces a new age ULIP, Future Generali Big Dreams Insurance Plan

Honda 2Wheelers India drives Skill India Mission in Tamil Nadu

Rane NSK Opens New Facility for EPS at Gujarat

GoAir reports highest OTP for second consecutive month!

ICAI signs MoU with CPA Canada

Square Capital Emerges as the Largest Integrated Mortgage Marketplace in India

Fresh impetus to the MSME sector - Acuité Ratings

GoAir's 13th Anniversary Offer: Up to 13 Lakh seats on sale at an all-inclusive price of Rs 1,313

India's plastics export jump 31.6% in H1 2018-19 to USD 4.59 bn

Homes worth Rs 1200 crore sold during Housing.com's Home Ustav 2018

Not just top 5 cities, now Tier III cities also contributing to retail participation in stock markets

Lighthouse invests 160 Crore in mattress company Duroflex

Kreditech licensed by Reserve Bank of India to operate as NBFC

Next Education partners with Capgemini as Edu-tech enabler

Co-origination lending: A potential solution to NBFCs' funding challenges

Honda 2Wheelers India expands its global footprint ahead of 2020

'All Weather Investing' - asset allocation with ETFs launched on smallcase.com

NPCI organises digital training workshops at 50 plus educational institutes on teacher's day

AVIVA launches Online Will Writing Service to Promote Financial Literacy







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019